R
Ryan Melchior
Researcher at Virginia Commonwealth University
Publications - 16
Citations - 1272
Ryan Melchior is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Anakinra & Myocardial infarction. The author has an hindex of 11, co-authored 16 publications receiving 974 citations. Previous affiliations of Ryan Melchior include MedStar Washington Hospital Center.
Papers
More filters
Journal ArticleDOI
Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].
Antonio Abbate,Benjamin W. Van Tassell,Giuseppe Biondi-Zoccai,Michael C. Kontos,John D. Grizzard,Debra Whittaker Spillman,Claudia Oddi,Charlotte S. Roberts,Ryan Melchior,George Mueller,Nayef Abouzaki,Lenore Rosemary Rengel,Amit Varma,Michael Lucas Gambill,Raquel Appa Falcao,Norbert F. Voelkel,Charles A. Dinarello,George W. Vetrovec +17 more
TL;DR: Interleukin-1 blockade with anakinra blunted the acute inflammatory response associated with ST-segment elevation acute myocardial infarction and led to a numerically lower incidence of heart failure in this cohort of clinically stable patients with near-normal LV dimensions and function.
Iconographies supplémentaires de l'article : Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]
Antonio Abbate,Benjamin W. Van Tassell,G Biondi-Zoccai,Michael C. Kontos,John D. Grizzard,Debra Whittaker Spillman,Claudia Oddi,Charlotte Susan Roberts,Ryan Melchior,George Mueller,Nayef Abouzaki,Lenore Rosemary Rengel,Amit Varma,Michael Lucas Gambill,Raquel Appa Falcao,Norbert F. Voelkel,Charles A. Dinarello,George W. Vetrovec +17 more
Journal ArticleDOI
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)
Benjamin W. Van Tassell,Justin M. Canada,Salvatore Carbone,Cory R. Trankle,Leo F. Buckley,Claudia Oddi Erdle,Nayef Abouzaki,Dave L. Dixon,Dinesh Kadariya,Sanah Christopher,Aaron Schatz,Jessica A. Regan,Michele Viscusi,Marco Giuseppe Del Buono,Ryan Melchior,Pranav Mankad,Juan Lu,Robin Sculthorpe,Giuseppe Biondi-Zoccai,Edward J. Lesnefsky,Ross Arena,Antonio Abbate +21 more
TL;DR: In this paper, the IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic heart failure.
Journal ArticleDOI
Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).
Antonio Abbate,Michael C. Kontos,Nayef Abouzaki,Ryan Melchior,Christopher S. Thomas,Benjamin W. Van Tassell,Claudia Oddi,Salvatore Carbone,Cory R. Trankle,Charlotte S. Roberts,George Mueller,Michael Lucas Gambill,Sanah Christopher,Roshanak Markley,George W. Vetrovec,Charles A. Dinarello,Giuseppe Biondi-Zoccai +16 more
TL;DR: IL-1 blockade with anakinra for 2 weeks appears to have a neutral effect on recurrent ischemic events, whereas it may prevent new-onset heart failure long term after STEMI.
Journal ArticleDOI
Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.
Antonio Abbate,Cory R. Trankle,Leo F. Buckley,Michael J. Lipinski,Darryn L. Appleton,Dinesh Kadariya,Justin M. Canada,Salvatore Carbone,Charlotte S. Roberts,Nayef Abouzaki,Ryan Melchior,Sanah Christopher,Jeremy Turlington,George Mueller,James P. Garnett,Christopher S. Thomas,Roshanak Markley,George F. Wohlford,Laura Puckett,Horacio Medina de Chazal,Juan Guido Chiabrando,Edoardo Bressi,Marco Giuseppe Del Buono,Aaron Schatz,Chau Vo,Dave L. Dixon,Giuseppe Biondi-Zoccai,Michael C. Kontos,Benjamin W. Van Tassell +28 more
TL;DR: In patients presenting with ST‐segment–elevation myocardial infarction, interleukin‐1 blockade with anakinra significantly reduces the systemic inflammatory response compared with placebo.